MedTrace Logo

Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant

NCT04488432 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2020-09-11

No results posted yet for this study

Summary

Allogeneic hematopoietic stem cell transplantations (allo-HSCT) is often indicated in malignant hematologic diseases. Conditioning regimens, used to reduce the tumor burden and to prevent transplant rejection, are based on chemotherapy alone or combined with total body irradiation (TBI). Endocrine complications are frequent transplant-related side effects. Investigators have been well described in children studies but less in adulthood.

The objective of this study is to assess retrospectively endocrine, bone and metabolic disorders in adult patients, 12 months after allo-HSCT.

Conditions

Sponsors & Collaborators

  • University Hospital, Brest

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-27
Primary Completion
2019-11-27
Completion
2019-11-27

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488432 on ClinicalTrials.gov